Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

Benzinga04:43

Is Bristol-Myers Squibb Company (BMY) the Best Stock to Invest In For Steady Dividends?

Yahoo Finance02:18

Bristol-Myers Squibb Company (NYSE:BMY) Is Largely Controlled by Institutional Shareholders Who Own 77% of the Company

Yahoo FinanceJan 21 21:00

Revenue is expected to increase by 932%! Baile Tianheng: Expected to turn a profit in 2024.

① Aside from the initial payment of 0.8 billion dollars, the cooperation announcement at that time indicated that the potential total Trade amount between BMS and Bai Li Tian Heng's subsidiary could reach up to 8.4 billion dollars. ② As of now, Bai Li Tian Heng has advanced three drugs to the Phase III registration clinical research stage, developed ten early-stage core clinical Assets, and a series of preclinical Innovative Drugs projects.

cls.cnJan 20 22:55

Hong Kong stocks movement | Ark Health surged 19.5% at one point after reaching a Global Strategy cooperation with Bristol-Myers Squibb in China.

Gelonghui January 20 | Ark Health (6086.HK) initially surged 19.5% to HKD 2.39. On the news front, on December 16, Ark Health signed a strategic cooperation agreement with Bristol-Myers Squibb in China. The two parties will conduct in-depth cooperation in areas such as the construction of digital health platforms and the upgrade of Internet health management models, and jointly explore new pathways for innovative development in Digital Health. It is reported that this strategic cooperation will focus on in-depth collaboration regarding the treatment drug riblocer and the psoriasis treatment drug secukinumab, exploring innovative digital marketing project management models. Notably, riblocer

Gelonghui FinanceJan 20 10:48

Why Bristol-Myers Squibb (BMY) Is One of the Best Cheap Stocks to Buy for 2025?

Yahoo FinanceJan 19 06:01